Ron Beaver, PhDback to Management Team>
Cofounder, President, and CEO
Dr. Beaver is an experienced entrepreneurial executive who has founded several successful ventures. His unique expertise lies in creating and leading companies that provide highly effective technical solutions to the challenges faced by complex customer organizations such as those in the biopharmaceutical industry.
Dr. Beaver is a co-founder of Rosa and the chief architect of its innovative structure. Under Dr. Beaver’s leadership, Rosa teams develop pharmacometric models - statistical or physiologic models of drug-disease behavior, in support of decisions such as compound prioritization and dose selection, and document the models and results for use in communication with both the US FDA and other regulatory agencies. Rosa is unique in that it also conducts cutting-edge market modeling in support of decisions such as the positioning of novel genomics-based diagnostic tests, creation of innovative pricing models, and the development of products for chronic, multi-stage diseases.
Prior to co-founding Rosa, Dr. Beaver worked with a global pharmaceutical firm to structure an open-source drug development group, focusing on both economic and organizational issues.
Dr. Beaver was also a co-founder of Pharsight Corporation’s consulting services, which under his leadership conducted more than 100 clinical trial optimization and asset strategy projects for both major and emerging bio-pharmaceutical companies. Pharsight was the first-generation company that drove large-scale adoption of drug-disease modeling and simulation within both the industry and its regulatory agencies. The team working under Dr. Beaver achieved major technical breakthroughs in modeling the pharmacokinetics and pharmacodynamics of HIV/AIDS.
Before joining Pharsight, Dr. Beaver was a co-founder and principal of the Pope Street Group (PSG), a strategic management consultancy and venture incubator. PSG incubated Starmine, Inc., a now-prominent financial services firm originally backed by established Silicon Valley venture capital groups and recently purchased by Thomson Reuters. At PSG, Dr. Beaver developed a long-run commodity pricing model for North American natural gas prices that accurately predicted the effect of pipeline constraints and geographical differences in supply economics and demand levels.
Prior to founding PSG, Dr. Beaver was an associate at Strategic Decisions Group (SDG). Dr. Beaver’s pioneering work in modeling regional electricity prices under the transition from regulated to competitive generation markets led to a series of multi-million dollar projects for SDG’s Utilities practice.
Dr. Beaver holds a doctorate in engineering from Stanford University and an undergraduate degree in engineering and liberal arts from Iowa State University and Simpson College. He served on the Board of Trustees of Simpson College.
Dr. Beaver was a member of Big-8 (now Big-12) championship and nationally top-ranked track and cross-country teams. He is currently one of the top Masters’-category bicycle racers in the Pacific Northwest, with multiple podium placings in regional road races and state championship events.